Full Press Release Details
| Dr. Reddy s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. | ||
| CIN : L85195TG1984PLC004507 | ||
| Tel :+91 40 4900 2900 | ||
| Fax :+91 40 4900 2999 | ||
| Email: mail@drreddys.com | ||
| www.drreddys.com |
| Surveillance Department | National Stock Exchange of India Ltd. | |||||
| BSE Limited | Exchange Plaza | |||||
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), | |||||
| Mumbai 400 001 | Mumbai 400 051 | |||||
| Fax Nos.: | 022-22723121 / 22723719 / | Fax Nos.: | 022-26598120/26598237/ | |||
| 22722037 / 22722039 | 26598238 | |||||
| Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
email dated March 21, 2017
Sub: Clarification on news item appeared on ET NOW dated March 21, 2017 captioned US FDA finds repeat
observations from 2015 warning letter. Failed to maintain complete data to ensure compliance.
This is with reference to your email dated
March 21, 2017, seeking clarification on the above subject.
In this regard, the Company has already intimated the Stock Exchanges vide our
letter dated March 8, 2017 stating that The audit of our formulation facility at Duvvada, Vishakhapatnam, by the US FDA has been completed today. We have been issued a Form-483 with 13 observations, which we are addressing.
We regularly inform all concerned on material events and at present we are not having any other information which is material to the Company s operations
or consolidated results.
Further, the movement in price of Company s scrip is completely market driven and hence the Company has no comments to
offer on share price movement.
However, as far as the 483 observations are concerned, the Company is preparing a comprehensive response and will submit
it to the US FDA within the stipulated time.
This is for your information and record.
CC:- New York Stock Exchange Inc. (Stock